Recently, Muniyappa et al. [115] found that patients affected by lipodystrophy treated with metreleptin showed a marked reduction in circulating ANGPTL3 levels together with a consistent improvement in liver steatosis, whereas ANGPTL4 levels remained unchanged [115]. The gene discussed is ANGPTL3; the disease is lipodystrophy.